Compare RVPH & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVPH | INVE |
|---|---|---|
| Founded | 2006 | 1990 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 119.1M |
| IPO Year | N/A | 1997 |
| Metric | RVPH | INVE |
|---|---|---|
| Price | $0.84 | $5.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $72.00 | $5.50 |
| AVG Volume (30 Days) | ★ 386.4K | 342.7K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $60,219,000.00 |
| Revenue This Year | N/A | $22.10 |
| Revenue Next Year | N/A | $20.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.21 |
| 52 Week Low | $0.17 | $3.08 |
| 52 Week High | $3.11 | $5.30 |
| Indicator | RVPH | INVE |
|---|---|---|
| Relative Strength Index (RSI) | 47.37 | 69.51 |
| Support Level | $0.44 | $3.25 |
| Resistance Level | $0.86 | N/A |
| Average True Range (ATR) | 0.07 | 0.30 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 38.93 | 84.67 |
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
Identiv Inc develops specialty radio-frequency identification (RFID) and Internet of Things It (IoT) solutions that address customers' challenges and create new opportunities for them through the digitization and enhanced connectivity to the IoT. It designs, produces, and sells RFID and Bluetooth Low Energy (BLE) enabled devices, RFID inlays, tags, and labels that can be applied or incorporated into physical objects, providing them with a digital identity and the ability for customers to track, monitor, authenticate, and engage with consumers. Its IoT Business segment develops, manufactures, and supplies specialty IoT solutions tailored for the healthcare, logistics, smart packaging industries and other high-value end markets.